Roth Capital Initiates Coverage On Mydecine Innovations with Buy Rating, Announces Price Target of C$3

Benzinga · 06/22/2021 13:03
Roth Capital analyst Elemer Piros initiates coverage on Mydecine Innovations (NEO: MYCO) with a Buy rating and announces Price Target of C$3.